Hormone Therapy for Prostate Cancer

  • Gairin J. Dancey
  • Jonathan Waxman


Prostate cancer is now the most prevalent of all male malignancies and the second most common cause of male cancer deaths. Death rates have trebled over the last 30 years, and changes in mortality during this period are shown in Table 3.1 [1].


Prostate Cancer Androgen Receptor GnRH Agonist Adjuvant Hormonal Therapy Watchful Waiting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Office for National Statistics. Mortality Statistics: Cause (Series DH2). HMSO, 2003.Google Scholar
  2. 2.
    Holmberg L, Bill-Axelson A., Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781–789.PubMedCrossRefGoogle Scholar
  3. 3.
    Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013–1021.PubMedGoogle Scholar
  4. 4.
    Vicini FA, Kini VR, Spencer W, Diokno A, Martinez AA. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1999;43:707–713.PubMedCrossRefGoogle Scholar
  5. 5.
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–106.PubMedCrossRefGoogle Scholar
  6. 6.
    Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96–99.PubMedGoogle Scholar
  7. 7.
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839–845.PubMedCrossRefGoogle Scholar
  8. 8.
    Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566–1572.PubMedGoogle Scholar
  9. 9.
    Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323–3329.PubMedCrossRefGoogle Scholar
  10. 10.
    Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996;78:921–927.PubMedGoogle Scholar
  11. 11.
    Dhillon T, Waxman J. Osteoporosis and prostate cancer. Br J Cancer 2003;89:779–780.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Gairin J. Dancey
    • 1
  • Jonathan Waxman
    • 2
  1. 1.Department of Medical OncologyCharing Cross HospitalLondonUK
  2. 2.Department of Oncology, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics (SORA), Faculty of MedicineImperial College London, Hammersmith HospitalLondonUK

Personalised recommendations